Esperion Therapeutics (ESPR) News Today → Guard Against the Coming Financial Upheaval (From Porter & Company) (Ad) Free ESPR Stock Alerts $2.36 -0.23 (-8.88%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 17 at 3:38 AM | americanbankingnews.comEsperion Therapeutics (NASDAQ:ESPR) Cut to "Buy" at StockNews.comMay 16 at 2:56 PM | marketbeat.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) Short Interest Up 6.8% in AprilEsperion Therapeutics, Inc. (NASDAQ:ESPR - Get Free Report) saw a large increase in short interest in April. As of April 30th, there was short interest totalling 19,870,000 shares, an increase of 6.8% from the April 15th total of 18,600,000 shares. Based on an average daily trading volume, of 6,820,000 shares, the days-to-cover ratio is presently 2.9 days. Currently, 11.8% of the company's stock are short sold.May 15, 2024 | americanbankingnews.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) Given Consensus Recommendation of "Hold" by BrokeragesMay 15, 2024 | marketbeat.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Average Recommendation of "Hold" from BrokeragesEsperion Therapeutics, Inc. (NASDAQ:ESPR - Get Free Report) has earned a consensus rating of "Hold" from the five ratings firms that are covering the firm, MarketBeat reports. Three investment analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on theMay 14, 2024 | finanznachrichten.deEsperion Therapeutics, Inc.: Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL and NEXLIZETMay 14, 2024 | globenewswire.comEsperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®May 13, 2024 | americanbankingnews.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) to Post Q2 2024 Earnings of ($0.16) Per Share, HC Wainwright ForecastsMay 12, 2024 | americanbankingnews.comHC Wainwright Weighs in on Esperion Therapeutics, Inc.'s FY2026 Earnings (NASDAQ:ESPR)May 11, 2024 | marketbeat.comMonaco Asset Management SAM Sells 928,137 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR)Monaco Asset Management SAM lowered its stake in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 79.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 243,642 shares of the biopharmaMay 11, 2024 | americanbankingnews.comAnalysts Offer Predictions for Esperion Therapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:ESPR)May 10, 2024 | globenewswire.comEsperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)May 10, 2024 | marketbeat.comHC Wainwright Brokers Cut Earnings Estimates for Esperion Therapeutics, Inc. (NASDAQ:ESPR)Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - HC Wainwright lowered their FY2026 earnings estimates for Esperion Therapeutics in a note issued to investors on Wednesday, May 8th. HC Wainwright analyst J. Pantginis now forecasts that the biopharmaceutical company will earn $2.19 per shMay 10, 2024 | americanbankingnews.comHC Wainwright Reiterates "Buy" Rating for Esperion Therapeutics (NASDAQ:ESPR)May 9, 2024 | americanbankingnews.comFY2026 EPS Estimates for Esperion Therapeutics, Inc. Cut by Analyst (NASDAQ:ESPR)May 8, 2024 | msn.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) Q1 2024 Earnings Call TranscriptMay 8, 2024 | markets.businessinsider.comEsperion Gains Buy Rating on Strong Sales Growth and Strategic ProgressMay 8, 2024 | marketbeat.comEsperion Therapeutics (NASDAQ:ESPR) Given "Buy" Rating at HC WainwrightHC Wainwright reissued a "buy" rating and set a $16.00 price target on shares of Esperion Therapeutics in a research report on Wednesday.May 8, 2024 | marketbeat.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) Expected to Earn FY2026 Earnings of $1.44 Per ShareEsperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Investment analysts at Zacks Research cut their FY2026 earnings estimates for Esperion Therapeutics in a research report issued on Monday, May 6th. Zacks Research analyst K. Das now expects that the biopharmaceutical company will post earnMay 8, 2024 | finance.yahoo.comEsperion Therapeutics Inc (ESPR) Q1 2024 Earnings Call Transcript Highlights: Soaring Revenues ...May 7, 2024 | marketwatch.comEsperion Shares Jump on Strong 1Q Results Above Analyst ExpectationsMay 7, 2024 | finance.yahoo.comEsperion Therapeutics Inc (ESPR) Surpasses Q1 Revenue Forecasts with a 467% IncreaseMay 7, 2024 | marketbeat.comEsperion Therapeutics' (ESPR) Buy Rating Reaffirmed at Needham & Company LLCNeedham & Company LLC reaffirmed a "buy" rating and issued a $8.00 price target on shares of Esperion Therapeutics in a report on Tuesday.May 7, 2024 | marketbeat.comEsperion Therapeutics Target of Unusually High Options Trading (NASDAQ:ESPR)Esperion Therapeutics, Inc. (NASDAQ:ESPR - Get Free Report) was the target of unusually large options trading on Tuesday. Stock investors purchased 6,387 call options on the company. This is an increase of 60% compared to the average daily volume of 3,991 call options.May 7, 2024 | investorplace.comESPR Stock Earnings: Esperion Therapeutics Beats EPS, Beats Revenue for Q1 2024May 7, 2024 | investorplace.comWhy Is Esperion Therapeutics (ESPR) Stock Up 13% Today?May 7, 2024 | washingtonpost.comEsperion Therapeutics: Q1 Earnings SnapshotMay 7, 2024 | globenewswire.comEsperion Reports First Quarter 2024 Financial ResultsMay 1, 2024 | marketbeat.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) Short Interest Down 6.6% in AprilEsperion Therapeutics, Inc. (NASDAQ:ESPR - Get Free Report) was the recipient of a significant drop in short interest in April. As of April 15th, there was short interest totalling 18,600,000 shares, a drop of 6.6% from the March 31st total of 19,920,000 shares. Based on an average daily trading volume, of 6,230,000 shares, the short-interest ratio is currently 3.0 days. Currently, 11.0% of the shares of the stock are short sold.May 1, 2024 | nasdaq.comEsperion Therapeutics, Inc. Common Stock (ESPR)May 1, 2024 | marketbeat.comEquities Analysts Set Expectations for Esperion Therapeutics, Inc.'s Q4 2025 Earnings (NASDAQ:ESPR)Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Equities researchers at Zacks Research decreased their Q4 2025 earnings per share estimates for Esperion Therapeutics in a note issued to investors on Monday, April 29th. Zacks Research analyst K. Das now expects that the biopharmaceuticalApril 30, 2024 | marketbeat.comEsperion Therapeutics (ESPR) to Release Quarterly Earnings on TuesdayEsperion Therapeutics (NASDAQ:ESPR) will be releasing earnings before the market opens on Tuesday, May 7, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=587743)April 30, 2024 | marketbeat.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) Expected to Post FY2025 Earnings of $0.02 Per ShareEsperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Equities researchers at Zacks Research reduced their FY2025 earnings estimates for Esperion Therapeutics in a research report issued on Monday, April 29th. Zacks Research analyst K. Das now expects that the biopharmaceutical company will pApril 29, 2024 | globenewswire.comEsperion to Participate in Upcoming May Investor ConferencesApril 23, 2024 | finance.yahoo.comEsperion to Report First Quarter 2024 Financial Results on May 7April 21, 2024 | finance.yahoo.com11 Best Low Price Pharma Stocks To Invest InApril 10, 2024 | marketbeat.comNeedham & Company LLC Reaffirms "Buy" Rating for Esperion Therapeutics (NASDAQ:ESPR)Needham & Company LLC reaffirmed a "buy" rating and issued a $8.00 price objective on shares of Esperion Therapeutics in a research note on Wednesday.April 8, 2024 | marketbeat.comEsperion Therapeutics (NASDAQ:ESPR) Trading Down 3.1%Esperion Therapeutics (NASDAQ:ESPR) Stock Price Down 3.1%April 8, 2024 | msn.comEsperion stock jumps as non-statin therapy shows clinical benefits across diverse patient groupsApril 7, 2024 | globenewswire.comEsperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with ObesityApril 5, 2024 | marketbeat.comZacks Research Weighs in on Esperion Therapeutics, Inc.'s Q3 2024 Earnings (NASDAQ:ESPR)Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Stock analysts at Zacks Research decreased their Q3 2024 earnings per share estimates for Esperion Therapeutics in a research note issued on Tuesday, April 2nd. Zacks Research analyst K. Das now expects that the biopharmaceutical company wApril 4, 2024 | marketbeat.comEsperion Therapeutics (NASDAQ:ESPR) Reaches New 12-Month High at $3.40Esperion Therapeutics (NASDAQ:ESPR) Hits New 52-Week High at $3.40April 4, 2024 | marketbeat.comFY2025 EPS Estimates for Esperion Therapeutics, Inc. Cut by Zacks Research (NASDAQ:ESPR)Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Zacks Research reduced their FY2025 earnings estimates for Esperion Therapeutics in a note issued to investors on Tuesday, April 2nd. Zacks Research analyst K. Das now anticipates that the biopharmaceutical company will post earnings of $0April 3, 2024 | msn.comSignet Jewelers, Dave & Buster's Entertainment, Blue Owl Capital And Other Big Stocks Moving Higher On WednesdayApril 1, 2024 | marketbeat.comEsperion Therapeutics (NASDAQ:ESPR) Trading 5.2% Higher Esperion Therapeutics (NASDAQ:ESPR) Trading 5.2% HigherApril 1, 2024 | globenewswire.comEsperion to Ring Nasdaq Opening Bell Today, April 1, 2024March 27, 2024 | marketbeat.comEsperion Therapeutics (NASDAQ:ESPR) Shares Gap Up to $2.70Esperion Therapeutics (NASDAQ:ESPR) Shares Gap Up to $2.70March 27, 2024 | marketbeat.comHC Wainwright Equities Analysts Decrease Earnings Estimates for Esperion Therapeutics, Inc. (NASDAQ:ESPR)Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Investment analysts at HC Wainwright cut their FY2026 earnings per share estimates for shares of Esperion Therapeutics in a research note issued on Monday, March 25th. HC Wainwright analyst J. Pantginis now expects that the biopharmaceuticMarch 26, 2024 | marketbeat.comEsperion Therapeutics (NASDAQ:ESPR) Sees Unusually-High Trading VolumeEsperion Therapeutics (NASDAQ:ESPR) Sees Strong Trading VolumeMarch 26, 2024 | finance.yahoo.comEsperion to Participate in 23rd Annual Needham Virtual Healthcare ConferenceMarch 26, 2024 | msn.comWhy Is Heart Disease-Focused Esperion Therapeutics Stock Trading Higher On Monday? Get Esperion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter. Email Address Guard Against the Coming Financial Upheaval (Ad)America’s Most Shocking Financial Story… Behind closed doors in D.C., there is a dark political and economic plot underway. That’s why if you have any savings in the bank or own any assets you want to protect, you must watch this new documentary before it’s too late. You can stream it for free right here. ESPR Media Mentions By Week ESPR Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ESPR News Sentiment▼0.330.42▲Average Medical News Sentiment ESPR News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ESPR Articles This Week▼113▲ESPR Articles Average Week Get Esperion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: PepGen News Today Revance Therapeutics News Today Acelyrin News Today Neurogene News Today Lexicon Pharmaceuticals News Today Theravance Biopharma News Today Korro Bio News Today Heron Therapeutics News Today Biomea Fusion News Today Annexon News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ESPR) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaUrgent Nvidia WarningAltimetryThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsCrypto Pioneer Says: “The last crypto bull market has begun.”InvestorPlaceBill Gates is all about this tiny $2 stockTimothy SykesCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingMost important medical advance in 100 yearsThe Oxford ClubMissed NVDA? Buy this AI stock NOWChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Esperion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
